Dendritic Cell Based Therapy for Breast Cancer Patients
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to investigate time to progression in breast cancer patients
vaccinated with autologous dendritic cells pulsed with peptides in combination with adjuvant
aromatase inhibitor (AI), Thymosin 1 alpha and interleukin-2. The secondary aim is to
investigate whether a measurable immune response can be induced, and to evaluate the clinical
effect (objective response rate) of the vaccination regime.